<DOC>
	<DOC>NCT01832818</DOC>
	<brief_summary>The objective of this study is to evaluate long-term safety and effectiveness of the NuNec® Cervical Arthroplasty System in a small patient population. The NuNec device is currently CE marked and commercially available in Europe.</brief_summary>
	<brief_title>Post-Market Study Evaluating the Safety and Effectiveness of NuNec® Cervical Arthroplasty System</brief_title>
	<detailed_description>The NuNec® feasibility study is a prospective, multi-centered, non-randomized clinical trial. Only patients who have been diagnosed with single level, C3 to C7, symptomatic cervical degenerative disc disease and have failed at least 6 weeks of conservative treatment or present signs of progression of spinal cord/nerve root compression with continued non-operative care will be enrolled. Patients will be evaluated preoperatively and postoperatively at discharge, 6 weeks, 3, 6, 12 and 24 months.</detailed_description>
	<mesh_term>Intervertebral Disc Degeneration</mesh_term>
	<criteria>is at least 21 years of age and skeletally mature must have symptomatic degenerative disc disease at one level in the cervical spine, C3 to C7, demonstrated by herniated disc and/or spondylosis; must have completed a minimum of six weeks of unsuccessful conservative, nonoperative care or has the presence of progressive symptoms or signs of nerve root/spinal cord compression in the face of conservative treatment must score at least 15/50 (30%) on the Neck Disability Index is willing and able to follow the postoperative management program must understand and sign the informed consent document symptomatic cervical DDD at more than one level axial neck pain as the primary diagnosis without evidence of neural compression neck or arm pain of unknown etiology any significant anatomical consideration which would make the anterior cervical approach excessively risky or impossible severe spondylosis at the target level prior surgery at the target level fused level adjacent to the target level osteoporosis, osteopenia, osteomalacia, Paget's disease or metabolic bone disease active infection or surgical site infection is using any medication known to interfere with bone/soft tissue healing diabetes mellitus requiring daily insulin management any terminal, systemic, or autoimmune disease medical conditions or mental incompetence which may interfere with study requirements BMI &gt;40 or a weight more than 100 lbs over ideal body weight chemical dependency problem that may interfere with study requirements current smokers history of any invasive malignancy unless treated and in remission for at least two years documented allergies to metal or plastic currently pregnant, or interested in becoming pregnant during the study followup</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Total Disc Replacement</keyword>
</DOC>